Redmond Asset Management LLC Invests $2.22 Million in Cellebrite DI Ltd. $CLBT

Key Points

• Redmond Asset Management LLC invested $2.22 million in Cellebrite DI Ltd., acquiring 114,317 shares of the company's stock.
• Cellebrite DI has reported a revenue increase of 18.4% year-over-year, reaching $113.28 million, and surpassed earnings estimates with $0.12 earnings per share.
• Institutional investors now hold 45.88% of Cellebrite DI's stock, with several firms, including Invesco and Handelsbanken, significantly increasing their stakes recently.

Redmond Asset Management LLC acquired a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 114,317 shares of the company's stock, valued at approximately $2,221,000.

Several other institutional investors and hedge funds also recently made changes to their positions in CLBT. Axon Enterprise Inc. acquired a new stake in Cellebrite DI during the 4th quarter valued at approximately $198,270,000. Invesco Ltd. lifted its holdings in shares of Cellebrite DI by 122.1% in the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after purchasing an additional 1,811,757 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Cellebrite DI by 749.9% during the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after acquiring an additional 1,340,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Cellebrite DI during the 1st quarter valued at $22,428,000. Finally, Nuveen LLC purchased a new stake in shares of Cellebrite DI during the 1st quarter valued at $15,031,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Stock Performance

NASDAQ CLBT traded down $0.4050 on Wednesday, reaching $15.3950. 528,657 shares of the stock traded hands, compared to its average volume of 1,666,414. The company has a fifty day moving average price of $14.96 and a 200-day moving average price of $17.67. The company has a market cap of $3.69 billion, a price-to-earnings ratio of -20.26, a PEG ratio of 3.20 and a beta of 1.27. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.Cellebrite DI's revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Needham & Company LLC reduced their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Wall Street Zen raised Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday. JPMorgan Chase & Co. lowered their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Finally, Lake Street Capital cut their target price on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.